This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Curtis Dobrowolski, PhD
Co-Founder at Nava Therapeutics


Curtis Dobrowolski graduated with a bachelors of science in biology from Jacksonville University in 2008 followed by a masters in Infectious disease and Immunology at the University of Sydney in 2010. In 2018 he completed his Ph.D. in molecular virology at Case Western Reserve University focusing on the reversal of HIV latency. Curtis then joined the James Dahlman lab at the Georgia Institute of Technology in 2019 as a postdoc to help develop a viral delivery system using lipid nanoparticles. With his extensive scRNA-sequencing experience he was able to create a high throughput LNP screening platform called SENT-seq. This technology was spun out into Nava Therapeutics, which utilizes high throughput screening of Lipid Nanoparticles in vivo using single cell RNA sequencing as our final readout.

Agenda Sessions

  • Identifying novel LNPs by Combining High Throughput Screening and Single Cell Multiomic Readouts